Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder that primarily manifests itself by progressive memory loss and cognitive decline, thus significantly affecting memory functions and quality of life. In this review, we proceed from the understanding that the canonical amyloid-β hypothesis, while significant, has faced setbacks, highlighting the need to adopt a broader perspective considering the intricate interplay of diverse pathological pathways for effective AD treatments. Sex differences in AD offer valuable insights into a better understanding of its pathophysiology. Fluctuation of the levels of ovarian sex hormones during perimenopause is associated with changes in glucose metabolism, as a possible window of opportunity to further understand the roles of sex steroid hormones and their associated receptors in the pathophysiology of AD. We review these dimensions, emphasizing the potential of estrogen receptors (ERs) to reveal mitochondrial functions in the search for further research and therapeutic strategies for AD pharmacotherapy. Understanding and addressing the intricate interactions of mitochondrial dysfunction and ERs potentially pave the way for more effective approaches to AD therapy.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Basic and Clinical Pharmacology and Toxicology |
| Vol/bind | 135 |
| Udgave nummer | 2 |
| Sider (fra-til) | 115-132 |
| Antal sider | 18 |
| ISSN | 1742-7835 |
| DOI | |
| Status | Udgivet - 2024 |
Bibliografisk note
Funding Information:Shokouh Arjmand thanks the Brain & Behavior Research Foundation and the Molly Lou Foundation for the award of the BBRF Young Investigator Grant, Grant Number 31803, during the tenure of which the manuscript was drafted.
Publisher Copyright:
© 2024 The Author(s). Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).